Sulfamethazine

Summary

Sulfamethazine (CHEMBL446) is an approved small-molecule antiinfective agent (ATC J01EB03); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01EB03
• Indications: 1 condition
• Chemistry: 278.33 Da · C12H14N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL446
Name	Sulfamethazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5327
ChEBI	CHEBI:102265
ATC	J01EB03
Molecular formula	C12H14N4O2S
Molecular weight	278.33
InChIKey	ASWVTGNCAZCNNR-UHFFFAOYSA-N

SMILES: CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C

IUPAC name: 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.

Pharmacological roles (ChEBI): antiinfective agent, carcinogenic agent, ligand, antibacterial drug, antimicrobial agent, EC 2.5.1.15 (dihydropteroate synthase) inhibitor, drug allergen.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: BN-2409, NSC-67457, NSC-683529, Smz-med 454, Sulfadimerazine, Sulfadimidina, Sulfadimidine, Sulfadimidinum, Sulfamethazine, Sulfamethazine component of lantrisul, Sulfamethazine component of neotrizine, Sulfamethazine component of sulfaloid

Parent form; salt/anhydrous children: CHEMBL1563050

Patent coverage: 4,477 distinct patent families (10,768 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Survival motor neuron protein, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	6	Potency	1000	nM	CHEMBL_ACT_3862808

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol,	CPIC	G6PD

PharmGKB also curates 0 clinical and 18 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).